Effects of MetAP2 inhibition on hyperphagia and body weight in Prader–Willi syndrome: A randomized, double-blind, placebo-controlled trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 12, 2017, Pages 1751-1761

  McCandless, Shawn E ^a   Yanovski, Jack A ^b   Miller, Jennifer ^c   Fu, Cary ^d   Bird, Lynne M ^e   Salehi, Parisa ^f   Chan, Christine L ^g   Stafford, Diane ^h   Abuzzahab, M Jennifer ⁱ   Viskochil, David ^j   Barlow, Sarah E ^k   Angulo, Moris ^l   Myers, Susan E ^m   Whitman, Barbara Y ^m   Styne, Dennis ⁿ   Roof, Elizabeth ^d   Dykens, Elisabeth M ^d   Scheimann, Ann O ^o   Malloy, Jaret ^p   Zhuang, Dongliang ^p   Taylor, Kristin ^p   Hughes, Thomas E ^p   Kim, Dennis D ^p   Butler, Merlin G ^q   more..

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e RADY CHILDREN'S HOSPITAL   (United States)

^f SEATTLE CHILDREN S HOSPITAL   (United States)

^g CHILDREN S HOSPITAL COLORADO   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^j UNIVERSITY OF UTAH   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l WINTHROP UNIVERSITY HOSPITAL   (United States)

^m SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ University of California at Davis School of Medicine   (United States)

^o JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p Zafgen Inc   (United States)

^q UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

more..

Author keywords

antiobesity drug; appetite control; clinical trial; phase III study; randomized trial

Indexed keywords

BELORANIB; PLACEBO; AMINOPEPTIDASE; ANOREXIGENIC AGENT; CINNAMIC ACID DERIVATIVE; CKD732; CYCLOHEXANE DERIVATIVE; EPOXIDE; GLYCOPROTEIN; METAP2 PROTEIN, HUMAN; PROTEINASE INHIBITOR; SESQUITERPENE;

ABNORMAL BEHAVIOR; ADOLESCENT; ADULT; AGED; AGGRESSION; ALOPECIA; ANXIETY; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERPHAGIA; INJECTION SITE CONTUSION; INJECTION SITE PAIN; IRRITABILITY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; OBESITY; PHASE 3 CLINICAL TRIAL; PRADER WILLI SYNDROME; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; WEIGHT CHANGE; ANTAGONISTS AND INHIBITORS; BODY MASS; BODY WEIGHT LOSS; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; EARLY TERMINATION OF CLINICAL TRIAL; INTENTION TO TREAT ANALYSIS; METABOLISM; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VEIN THROMBOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOPEPTIDASES; APPETITE DEPRESSANTS; BODY MASS INDEX; CINNAMATES; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; EPOXY COMPOUNDS; FEMALE; GLYCOPROTEINS; HUMANS; HYPERPHAGIA; INTENTION TO TREAT ANALYSIS; MALE; OBESITY; PRADER-WILLI SYNDROME; PROTEASE INHIBITORS; SESQUITERPENES; SEVERITY OF ILLNESS INDEX; VENOUS THROMBOSIS; WEIGHT LOSS; YOUNG ADULT;

EID: 85023632536     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13021     Document Type: Article

References (41)

1. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest. 2015;38:1249–1263.
2. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14:10–26.
3. Butler MG. Single gene and syndromic causes of obesity: illustrative examples. Prog Mol Biol Transl Sci. 2016;140:1–45.
4. Schrander-Stumpel CT, Curfs LM, Sastrowijoto P, Cassidy SB, Schrander JJ, Fryns JP. Prader-Willi syndrome: causes of death in an international series of 27 cases. Am J Med Genet A. 2004;124A:333–338.
5. Stevenson DA, Heinemann J, Angulo M, et al. Gastric rupture and necrosis in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr. 2007;45:272–274.
6. Stevenson DA, Heinemann J, Angulo M, et al. Deaths due to choking in Prader-Willi syndrome. Am J Med Genet A. 2007;143A:484–487.
7. Laurance BM, Brito A, Wilkinson J. Prader-Willi syndrome after age 15 years. Arch Dis Child. 1981;56:181–186.
8. Butler MG, Manzardo AM, Heinemann J, Loker C, Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet Med. 2017;19:635–642.
9. McCandless SE, Committee on Genetics. Clinical report-health supervision for children with Prader-Willi syndrome. Pediatrics. 2011;127:195–204.
10. Mazaheri MM, Rae-Seebach RD, Preston HE, et al. The impact of Prader-Willi syndrome on the family's quality of life and caregiving, and the unaffected siblings' psychosocial adjustment. J Intellect Disabil Res. 2013;57:861–873.
11. Scheimann AO, Butler MG, Gourash L, Cuffari C, Klish W. Critical analysis of bariatric procedures in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr. 2008;46:80–83.
12. Alqahtani AR, Elahmedi MO, Al Qahtani AR, Lee J, Butler MG. Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched-control study. Surg Obes Rel Dis. 2016;12:100–110.
13. Scheimann AO, Miller J, Glaze DG. Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched control study. Surg Obes Rel Dis. 2017;13:366.
14. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M. Speakers contributors at the second expert meeting of the comprehensive care of patients with PWS. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab. 2008;93:4183–4197.
15. Dykens E, Shah B. Psychiatric disorders in Prader-Willi syndrome: epidemiology and management. CNS Drugs. 2003;17:167–178.
16. Kim YM, An JJ, Jin YJ, et al. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol. 2007;38:455–465.
17. Rupnick MA, Panigrahy D, Zhang CY, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA. 2002;99:10730–10735.
18. Lijnen HR, Frederix L, Van Hoef B. Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. Obesity (Silver Spring). 2010;18:2241–2246.
19. White HM, Acton AJ, Considine RV. The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice. Obesity (Silver Spring). 2012;20:2003–2009.
20. Brakenhielm E, Cao R, Gao B, et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res. 2004;94:1579–1588.
21. Kim DD, Krishnarajah J, Lillioja S, et al. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab. 2015;17:566–572.
22. Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring). 2013;21:1782–1788.
23. Salehi P, Hsu I, Azen CG, Mittelman SD, Geffner ME, Jeandron D. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatr Obes. 2017;12:221–228.
24. Motaghedi R, Lipman EG, Hogg JE, Christos PJ, Vogiatzi MG, Angulo MA. Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome. Eur J Med Genet. 2011;54:14–18.
25. Deal CL, Tony M, Hoybye C, et al. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013;98:E1072–E1087.
26. Kennedy L, Bittel DC, Kibiryeva N, Kalra SP, Torto R, Butler MG. Circulating adiponectin levels, body composition and obesity-related variables in Prader-Willi syndrome: comparison with obese subjects. Int J Obes (Lond). 2006;30:382–387.
27. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–140.
28. Patel S, Harmer JA, Loughnan G, Skilton MR, Steinbeck K, Celermajer DS. Characteristics of cardiac and vascular structure and function in Prader-Willi syndrome. Clin Endocrinol (Oxf). 2007;66:771–777.
29. Butler MG, Bittel DC, Kibiryeva N, Garg U. C-reactive protein levels in subjects with Prader-Willi syndrome and obesity. Genet Med. 2006;8:243–248.
30. Hoybye C, Bruun JM, Richelsen B, Flyvbjerg A, Frystyk J. Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment. Eur J Endocrinol. 2004;151:457–461.
31. Haqq AM, Muehlbauer MJ, Newgard CB, Grambow S, Freemark M. The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J Clin Endocrinol Metab. 2011;96:E225–E232.
32. Weigle DS, Ganter SL, Kuijper JL, Leonetti DL, Boyko EJ, Fujimoto WY. Effect of regional fat distribution and Prader-Willi syndrome on plasma leptin levels. J Clin Endocrinol Metab. 1997;82:566–570.
33. Butler MG, Moore J, Morawiecki A, Nicolson M. Comparison of leptin protein levels in Prader-Willi syndrome and control individuals. Am J Med Genet. 1998;75:7–12.
34. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289:1799–1804.
35. Datta B, Majumdar A, Datta R, Balusu R. Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases. Biochemistry. 2004;43:14821–14831.
36. Kotzka J, Knebel B, Avci H, et al. Phosphorylation of sterol regulatory element-binding protein (SREBP)-1a links growth hormone action to lipid metabolism in hepatocytes. Atherosclerosis. 2010;213:156–165.
37. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab. 2008;19:65–73.
38. Jetten AM, Kang HS, Takeda Y. Retinoic acid-related orphan receptors alpha and gamma: key regulators of lipid/glucose metabolism, inflammation, and insulin sensitivity. Front Endocrinol. 2013;4:1.
39. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006;443:289–295.
40. Holsen LM, Zarcone JR, Brooks WM, et al. Neural mechanisms underlying hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring). 2006;14:1028–1037.
41. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015;15:130.